Brief: Oramed Pharmaceuticals - Oravax's Oral Covid-19 Vaccine Has Received South African Approval To Initiate Phase 1 Trial
29/10/2021 13:09
Oct 29 (Reuters) - Oramed Pharmaceuticals Inc ORMP.O :
* ORAMED ANNOUNCES ORAVAX'S ORAL COVID-19 VACCINE HAS RECEIVED SOUTH AFRICAN
APPROVAL TO INITIATE PHASE 1 TRIAL
* ORAMED - POST PHASE 1 TRIAL, INTENTION IS TO MOVE FORWARD WITH PHASE 2/3
TRIAL
FOR EMERGENCY USE APPROVAL OF COVID-19 VACCINE IN RELEVANT COUNTRIES
Source text for Eikon: ID:nPnkNb70a
Further company coverage: ORMP.O
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results